CareRx Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

CareRx wird ein Gewinn- und Umsatzwachstum von 29.1% bzw. 3.2% pro Jahr prognostiziert, während der Gewinn pro Aktie um 120% pro Jahr wachsen soll.

Wichtige Informationen

29.1%

Wachstumsrate der Gewinne

120.0%

EPS-Wachstumsrate

Consumer Retailing Gewinnwachstum	9.8%
Wachstumsrate der Einnahmen	3.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	12 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

OTCPK:CHHH.F - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CAD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	398	-3	N/A	N/A	4
12/31/2025	380	-4	17	23	8
12/31/2024	365	-3	27	33	8
9/30/2024	366	-6	31	38	N/A
6/30/2024	367	-7	27	34	N/A
3/31/2024	369	-4	23	32	N/A
12/31/2023	371	-5	19	27	N/A
9/30/2023	374	-6	25	33	N/A
6/30/2023	378	-7	30	38	N/A
3/31/2023	380	-34	16	29	N/A
12/31/2022	382	-34	9	22	N/A
9/30/2022	384	-34	-4	11	N/A
6/30/2022	358	-36	-5	10	N/A
3/31/2022	311	-20	-1	8	N/A
12/31/2021	263	-23	0	7	N/A
9/30/2021	212	-21	2	7	N/A
6/30/2021	187	-24	-6	-3	N/A
3/31/2021	177	-29	-2	0	N/A
12/31/2020	162	-18	-2	0	N/A
9/30/2020	148	-50	-3	-1	N/A
6/30/2020	134	-47	-2	0	N/A
3/31/2020	126	-34	-1	2	N/A
12/31/2019	125	-46	3	6	N/A
9/30/2019	122	-19	-1	3	N/A
6/30/2019	119	-20	-2	4	N/A
3/31/2019	117	-39	5	9	N/A
12/31/2018	119	-35	2	7	N/A
9/30/2018	85	-27	8	14	N/A
6/30/2018	97	-23	N/A	12	N/A
3/31/2018	110	-3	N/A	15	N/A
12/31/2017	122	-4	N/A	16	N/A
9/30/2017	168	-6	N/A	14	N/A
6/30/2017	170	-3	N/A	24	N/A
3/31/2017	170	-13	N/A	10	N/A
12/31/2016	167	-18	N/A	2	N/A
9/30/2016	166	-21	N/A	6	N/A
6/30/2016	166	-34	N/A	3	N/A
3/31/2016	164	-30	N/A	20	N/A
12/31/2015	161	-35	N/A	29	N/A
9/30/2015	27	-47	N/A	28	N/A
6/30/2015	60	-48	N/A	22	N/A
3/31/2015	97	-49	N/A	18	N/A
12/31/2014	135	-44	N/A	20	N/A
9/30/2014	301	-48	N/A	23	N/A
6/30/2014	295	-43	N/A	26	N/A
3/31/2014	289	-49	N/A	24	N/A
12/31/2013	281	-39	N/A	20	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CHHH.F wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: CHHH.F wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: CHHH.F wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: CHHH.FDie Einnahmen des Unternehmens (3.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: CHHH.FDie Einnahmen des Unternehmens (3.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CHHH.F in 3 Jahren voraussichtlich hoch sein wird

CareRx Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

CareRx Corporation to Report Q3, 2024 Results on Nov 08, 2024

CareRx Corporation Appoints Suzanne Brand as Chief Financial Officer, Effective October 1, 2024

CareRx Corporation to Report Q2, 2024 Results on Aug 08, 2024

CareRx Corporation Announces Board Changes

CareRx Corporation Announces CFO Transition

CareRx Corporation, Annual General Meeting, May 28, 2024

CareRx Corporation Reports Goodwill and Intangible Assets Impairment Charges for the Fourth Quarter Ended December 31, 2023

CareRx Corporation to Report Q4, 2023 Results on Mar 07, 2024

CareRx Corporation to Report Q3, 2023 Results on Nov 08, 2023

CareRx Corporation to Report Q2, 2023 Results on Aug 10, 2023

Carerx Corporation Announces Director Changes

CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million.

CareRx Corporation announced that it expects to receive CAD 8.0001 million in funding

CareRx Announces Retirement of Dr. Jack Shevel as Director Effective December 31, 2022

CareRx Corporation to Report Q3, 2022 Results on Nov 09, 2022

Carerx Corporation Reports Goodwill and Intangible Assets Impairment Changes for the Three Months Ended June 30, 2022

CareRx Corporation to Report Q2, 2022 Results on Aug 15, 2022

CareRx Corporation (TSX:CRRX) completed the acquisition of Hogan Pharmacy Partners Ltd.

CareRx Corporation to Report Q1, 2022 Results on May 11, 2022

CareRx Corporation Announces Executive Changes

CareRx Corporation, Annual General Meeting, Jun 07, 2022

CareRx Corporation (TSX:CRRX) entered into a definitive asset purchase agreement to acquire Hogan Pharmacy Partners Ltd for $4.4 million.

CareRx Corporation (TSX:CRRX) entered into a definitive asset purchase agreement to acquire Hogan Pharmacy Partners Ltd for $4.4 million.

Carerx Corporation Expands the Scope and Product Offering of Its Medical Supplies Business Under A New Brand, Revicare

CareRx Corporation (TSX:CRRX) completed the acquisition of Long-Term Care Pharmacy Division of Medical Pharmacies Group Limited for CAD 72.9 million.

CareRx Corporation (TSX:CRRX) completed the acquisition of pharmacy fulfillment centre and portion of long-term care pharmacy services business of Rexall Pharma Plus Ltd.

CareRx Corporation announced that it has received CAD 63.250644 million in funding from Yorkville Asset Management Inc.

CareRx Corporation (TSX:CRRX) acquired Fulfillment Centre in Thunder Bay, Ontario from Medical Pharmacies Group Limited.

CareRx Corporation (TSX:CRRX) entered into a definitive agreement to acquire pharmacy fulfillment centre and portion of long-term care pharmacy services business of Rexall Pharma Plus Ltd. for CAD 3.5 million.

CareRx Corporation announced that it expects to receive CAD 55.00056 million in funding from Yorkville Asset Management Inc.

CareRx Corporation to Report Q4, 2020 Results on Mar 10, 2021

CareRx Corporation and Think Research Corporation Announces Their Canada-Wide Partnership to Deliver Virtual Healthcare to Seniors

CareRx Corporation announced that it has received CAD 6.244997 million in funding from Yorkville Asset Management Inc., and other investor

CareRx Corporation announced that it expects to receive CAD 4.999998 million in funding from Yorkville Asset Management Inc., and another investor

CareRx Corporation Enters Multi-Year Pharmacy Services Agreement with an Ontario- Based Seniors Home Operator

CareRx Corporation Announces Appointment of Puneet Khanna as Senior Vice President, Corporate Development

CareRx Corporation to Report Q3, 2020 Results on Nov 05, 2020

CareRx Corporation to Report Q2, 2020 Results on Aug 06, 2020

Centric Health Corporation (TSX:CHH) completed the acquisition of Remedy Holdings Inc. from Remedy Capital Corporation, 2642943 Ontario Inc., 2745995 Ontario Inc, Jeff May and others.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken